首页> 外文OA文献 >SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY

【2h】

SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY

机译：LY3015014的安全性和有效性，它是一种具有蛋白原价更长的作用持续时间的蛋白转化蛋白水解酶/ KEXIN 9型（PCSK9）单克隆抗体，在原发性高胆固醇血症患者中进行了2例随机对照研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kastelein John; Nissen Steven; Rader Daniel; Krueger Kathryn; Wang Ming-Dauh;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study [J] . Kastelein John J. P., Nissen Steven E., Rader Daniel J., European Heart Journal: The Journal of the European Society of Cardiology . 2016,第17期

机译：LY3015014的安全性和有效性，这是一种针对前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（PCSK9）的单克隆抗体：一项随机，安慰剂对照的2期研究
2. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study [J] . Giugliano Robert P., Desai Nihar R., Kohli Payal, The Lancet . 2012,第9858期

机译：高胆固醇血症患者中抗原蛋白转化酶枯草杆菌蛋白酶/ kexin 9型单克隆抗体联合他汀类药物的疗效，安全性和耐受性（LAPLACE-TIMI 57）：一项随机，安慰剂对照，剂量范围，2期研究
3. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study ― [J] . Koutaro Yokote, Shigeto Kanada, Osamu Matsuoka, Circulation journal . 2017,第10期

机译：Bococizumab（RN316 / PF-04950615），一种针对原蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型的单克隆抗体，在高胆固醇血症的日本受试者中接受稳定剂量的阿托伐他汀或未接受治疗的日本受试者的疗效和安全性来自随机，安慰剂对照的剂量-范围研究―
4. Evaluation of the Interaction Between Proprotein Convertase Subtilisin/Kexin Type 9 and Sterol Carrier Protein-2 [D] . Ahranjani, Reza. 2017

机译：评价前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型与甾醇载体蛋白2的相互作用。
5. Safety and efficacy of LY3015014 a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized placebo-controlled Phase 2 study [O] . John J.P. Kastelein, Steven E. Nissen, Daniel J. Rader, -1

机译：LY3015014的安全性和有效性这是一种针对前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（PCSK9）的单克隆抗体：一项随机安慰剂对照的2期研究
6. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study [O] . John J.P. Kastelein, Steven E. Nissen, Daniel J. Rader, 2016

机译：LY3015014的安全性和功效，Proprotein转化酶枯草杆菌蛋白酶/ kexin型的单克隆抗体9（PCSK9）：A随机，安慰剂对照2研究

SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY

著录项

引文网络

相似文献

相关主题

期刊订阅